Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients.
about
High prevalence of both humoral and cellular immunity to Zaire ebolavirus among rural populations in GabonAnimal models for Ebola and Marburg virus infectionsAssembly of Ebola virus matrix protein VP40 is regulated by latch-like properties of N and C terminal tailsHuman fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosisCurrent ebola vaccinesClinical management of filovirus-infected patientsIntracellular events and cell fate in filovirus infectionFilovirus research in Gabon and equatorial Africa: the experience of a research center in the heart of AfricaQuantifying Poverty as a Driver of Ebola TransmissionMarburgvirus genomics and association with a large hemorrhagic fever outbreak in AngolaEmerging targets and novel approaches to Ebola virus prophylaxis and treatmentEbola haemorrhagic feverEbolavirus vaccines for humans and apesAntibody-dependent enhancement of Ebola virus infectionClinical development of Ebola vaccinesThe Role of Cytokines and Chemokines in Filovirus InfectionFiloviruses: One of These Things is (not) Like the OtherEbola Virus Disease (The Killer Virus): Another Threat to Humans and Bioterrorism: Brief Review and Recent UpdatesMouse models for filovirus infectionsNeutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against itEbolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppressionStructure of the Ebola virus glycoprotein bound to an antibody from a human survivorStructure of the Ebola VP35 interferon inhibitory domainStructural basis for dsRNA recognition and interferon antagonism by Ebola VP35Marburg Virus VP35 Can Both Fully Coat the Backbone and Cap the Ends of dsRNA for Interferon AntagonismThe Ebola Virus Interferon Antagonist VP24 Directly Binds STAT1 and Has a Novel, Pyramidal FoldEbolavirus VP35 Coats the Backbone of Double-Stranded RNA for Interferon Antagonism[Haemostasis dysregulation in filovirus infections].Chloroquine could be used for the treatment of filoviral infections and other viral infections that emerge or emerged from viruses requiring an acidic pH for infectivityEarly immune responses accompanying human asymptomatic Ebola infectionsGender-dependent specific immune response during chronic human Schistosomiasis haematobiaNeglected filovirusesDiagnosis of Ebola Virus Disease: Past, Present, and FutureDeaths, late deaths, and role of infecting dose in Ebola virus disease in Sierra Leone: retrospective cohort studyInterferon-γ Inhibits Ebola Virus InfectionBroad-Range Antiviral Activity of Hydrogen Sulfide Against Highly Pathogenic RNA VirusesProduction of Potent Fully Human Polyclonal Antibodies against Ebola Zaire Virus in Transchromosomal CattleImmune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPsA review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?Progress towards the treatment of Ebola haemorrhagic fever.
P2860
Q21090030-23BBEB64-F569-44A3-9F1E-B65BAFAC944EQ21131118-52BE1D26-D539-436A-8A74-36FC12E254B7Q21134356-E2BC2E28-F731-4273-A122-6CEF20C41093Q21144780-ECC1F2A8-41C4-4C77-B57E-D646B9D6E6BBQ21534720-CD7A3476-40BE-4863-9A70-B09251A5CFC7Q22305518-27EF6756-D813-4856-96C4-F571DA1CC77AQ22305521-160360D6-5734-44C2-B0DE-E10039F1EBBFQ24273305-28B0CD56-89BD-4AE5-A07F-D1EEBEDF355DQ24290713-56077D43-5734-44E2-84E9-44B7E5AB797DQ24548936-02B8BFF1-2270-4DDD-A227-110A6E708A21Q24597625-1730DAC9-283C-477C-9976-DD8E8D074B00Q24629338-7E54E718-1303-4659-B5CD-2D5A79182DB0Q24631696-C69D9C65-7176-40CE-AC51-30291E938A50Q24683154-41818AC7-5BC7-46EE-B2AE-DC0CEEC5910EQ26775792-7C5BA31D-6392-4DDE-B1EF-F43EEEA03C48Q26778003-69B53EAB-648A-48D3-B913-D51ED672A842Q26783063-57741E22-FD83-4D3F-925A-76D5C674D24AQ26798860-F22FEF1B-CC24-4751-B527-B59E86C4072AQ27011569-87B59CC5-6532-44A6-80AA-A0093E321440Q27489891-1BEEB083-E21E-41FB-8625-0F6AD23DF783Q27646608-35AC2116-CFD4-488D-ABC1-96C153C910E0Q27651112-4D4674EE-EF6A-4202-AE23-484E0F3906A1Q27653329-612DA9E2-9E87-49DE-ACB8-10342E51691BQ27659023-1AB7BF16-8816-4527-B756-294E8889FD41Q27673907-B7C609A5-7B20-4A27-B4D3-04221EFB3C23Q27677595-D024C916-001C-4576-904C-25F036D83125Q27678917-808D06AA-E159-47C8-BE72-46B07BC7B724Q27691452-CB0199D4-AF04-4330-A506-F9D4C4E6B76AQ28066142-D356DD2B-74A8-4AD6-BE99-4CF0E1452F6BQ28344889-E3834C35-AD60-415F-B1C1-59010F650EC7Q28365400-26377999-645B-457B-8EF2-A33976BBB11BQ28383265-9858EF9B-E511-4072-AB22-7580CADD1F57Q28388534-C698C0EC-1115-4679-93A1-26F2B37D751BQ28394474-8DBECD4E-D68C-48C0-B8BE-F1002AE0DE40Q28550929-1723F667-F549-4912-AB7C-5CDEB41079FFQ28582806-35D3A9F3-750D-44AB-888C-076C5A54C8F4Q28603849-73446B98-A005-4396-886D-7A763635E979Q28768041-FBB5BA7B-A55D-4133-A0DA-D4EDFFB8F14BQ29994671-ADB7176A-113E-43A4-A75B-5892376F6D51Q30230272-C60D24F3-0FD8-4CDB-8306-1B16B45AEE39
P2860
Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Defective humoral responses an ...... Ebola virus-infected patients.
@en
Defective humoral responses an ...... Ebola virus-infected patients.
@nl
type
label
Defective humoral responses an ...... Ebola virus-infected patients.
@en
Defective humoral responses an ...... Ebola virus-infected patients.
@nl
prefLabel
Defective humoral responses an ...... Ebola virus-infected patients.
@en
Defective humoral responses an ...... Ebola virus-infected patients.
@nl
P2093
P356
P1433
P1476
Defective humoral responses an ...... Ebola virus-infected patients.
@en
P2093
Fisher-Hoch SP
Georges AJ
Georges-Courbot MC
Lansoud-Soukate J
McCormick JB
P2888
P304
P356
10.1038/7422
P407
P577
1999-04-01T00:00:00Z